Quicklook

Honelako gehiago

OEI

Sarah Whylly‑k egina

CM - Chapter 3 - Why organizations change

Sander van der Kolk‑k egina

TYPES OF ENTERTAINMENT

Katherine Aragones‑k egina

Task Based Language Teaching

Belén Ichina‑k egina

Quicklook

4. Intellectual Property

Novelty

Technique lends itself toan automated

Patents

Prototype, patent proof.

Landscape

Opportunity for expansion and innovation.

First to file

The liquid core optical fiber LCOF

Priorant

Not new technology.

Freedom to aperate.

Mostly local.

5. Comercialization Planning.

Risk / Mitigation.

Errorous results

Raman net surtable for poin up care measurements.

Barries.

Ama review and stablishment of rembarsement processes

Federal agency that insprets medical laboratories.

Approrals from the clinval lateratery imparemen amendments (LIA).

Actting FDA approvalon to commercialization.

Sustentability

It is limited because Roman is still expensive.

Business Model

Intellectual property proyetion

Canvas

Core Activities

Pilot testing.

Creating a prototype .

The cost saving to the lab will need to be proven.

3. Comepetition.

Technical.

Technology.

Wokkforce.

Dinner.

Future

Existing.

Coulter.

Beckman/

R x IS

New.

Joe Skraba vice president of business developmen of lab now.

Market.

Direct NO COMPETITION

Indirect: RxIS Beckman/Cauter.

7. Proposed Activities

Projection.

Recomendation.

Ensure.

Perception

Information.

Measonng.

6. Financial Analysis.

Projection

Interface to apropriate diagnostic.

Equipament buying tends.

Insura implication.

Rapidly enough.

Seller value proposition

Direct competiton.

Blood work cost 20-30

$200.00 but used reforbished machines are aviable $9,995.$20,000

Customer Value poposition

Market can be $100-$300 mill.

It is stuck at price and speedbuel.

Roman is still expensive.

2. Market

Characteristics

1) Private and public hospitals.

Subtema

2) EE.UU Laboratories

Selection.

2) Austin Regional Clinics Lab Facilities.

1) Boston University Medical Center.

Interest

4) Veterinary offices.

3) Government laboratories.

2) In hospital laboratories.

1) Centralized laboraories.

Pain

5) Tretament dialysis.

4) Is fast and accurate.

3) The key indicator of renal failurz.

2) Requies a much smaller hood scimple from the patient.

1) Enhances accuracy of the analysis

1.Technology

Features.

3) The tube allows for the potential for real time

2) The tube can allow for an automated.

1) Use of the fiber optic core enhances.

Status

2) Patent proof.

1) Prototype.

Description

2) Not requiere the use of chemical reagents

1) Chemical diagnostic.

Risk/Mitigation

2) Entry of new technology.

1) Obsolete Technology.

Barriers

2) Expantion in yhe contrys.

1) Cost